On November 7, 2025, analyst Kevin DeGeeter of Ladenburg Thalmann initiated coverage of NextCure, Inc. (NASDAQ: NXTC) with a “Buy” rating and established a price target of $18. This recommendation comes at a time when the stock is trading at $9.82, suggesting considerable upside potential for investors. With such a bullish outlook, industry watchers are keen to explore what this means for potential investors in NextCure.
Recent Price Action
NextCure’s stock has demonstrated notable volatility over recent trading sessions. Currently priced at $9.82, NXTC has faced significant adversity, with a 52-week high of $265.33 representing an astounding decline of nearly 96%. Its recent performance reflects a change of approximately $0.14, or 1.42%, alongside a trading volume of 9,053 against an average volume of 36,982. This stock is also characterized by a beta of 1.558, suggesting it tends to experience greater price fluctuations compared to the broader market. The broader sentiment surrounding NXTC has been cautious, but recent analyst upgrades may spark renewed investor interest.
Short- and Long-Term Performance
A deeper look at NextCure’s recent performance indicates contrasting trends across different time horizons. Over the past 30 days, the stock has surged by an impressive 43.36%, reflecting a recovery phase as investors possibly reposition ahead of the analyst rating. The quarterly performance is strikingly robust at 101.64%, emphasizing its ability to rebound. However, this short-term performance contrasts starkly with the stock’s annual decline of 38.47%, a reflection of challenging macroeconomic conditions and sector-specific challenges. The stock’s weekly volatility of 10.95% and monthly volatility of 15.9% additionally echo the turbulent market conditions that next investors should consider.
Earnings / Financials
On November 5, 2025, NextCure reported an earnings per share (EPS) of -$3.22, which was better than the estimated EPS of -$4.06, resulting in a positive surprise factor of approximately 20.69%. This represents a recovery from the previous quarter when the actual EPS of -$11.29 missed estimates of -$4.62, with an extraordinary surprise percentage of 144.37% that raised serious concerns about its earnings predictability. While the latest EPS result indicates a narrowing in losses and could inspire confidence among potential investors, it underscores ongoing challenges that NextCure must address to achieve profitability.
Analyst / Consensus View
Currently, there is a strong consensus on NXTC, with Kevin DeGeeter being the sole analyst publicly rating the stock. His upgrade to a “Buy” status, alongside a consistent price target of $18, suggests optimism regarding the firm’s growth prospects. Given the limited number of ratings—a total of one “Buy” with no “Hold” or “Sell” designations—investor sentiment appears overwhelmingly positive, at least from this analyst’s perspective. This lack of opposing views could instill further confidence, though it is essential to consider the broader analytical landscape.
Stock Grading or Fundamental View
NextCure has received a Stocks Telegraph Grade (ST Score) of 33, indicating potential concerns regarding its overall health and investment appeal. Such a score suggests that while there is potential for upside, the company may also face significant fundamental challenges. Investors should carefully assess these fundamentals, especially in relation to industry trends and competitive dynamics.
Conclusion
In summary, NextCure, Inc. (NXTC) presents a complex investment case. The recent “Buy” rating from Ladenburg Thalmann and robust short-term performance signal potential for upside, particularly for risk-tolerant investors willing to navigate volatility. However, the steep historical decline, ongoing losses, and mixed earnings outlook necessitate a cautious approach. Long-term investors may appreciate the speculative upside if the company can stabilize its operations and begin demonstrating sustainable growth patterns. For those considering entry, understanding the inherent risks associated with NXTC is critical before committing capital.